Answers are grounded in this paper and cite their sources.
This editorial refers to ‘The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis’†, by S. Xu et al., on page 2398. Coronary artery disease (CAD) is one of the leading causes of mortality in the world and is triggered by different risk factors, including diet, dyslipidaemia, diabetes, inflammation, and, importantly, also genetics.1,2 Indeed, heritable factors account for 40–60% of the risk of developing CAD,1 and genome-wide association studies (GWAS) have the potential to identify genetic variations associated with CAD. The first GWAS for CAD was published in 2007,3 which initiated an exciting era of cardiovascular systems genetics (also described as systems medicine) to detect new loci associated with cardiovascular complications.4 Although several follow-up studies led to the identification of various genetic polymorphisms that are associated with increased incidence of CAD or myocardial infarction (MI), including single nucleotide polymorphisms (SNPs), these identified variants only explain ∼10% of the risk heritability.4 One of the best ways to validate the cardiovascular function of genetic variants is to study their role in genetically modified model organisms.5,6 Importantly, a systematic review from von Scheidt et al. demonstrated that most CAD risk variants from GWAS display consistent phenotypes in experimental atherosclerosis mouse models.7 Several GWAS studies have identified genetic variants at the junctional cadherin 5 associated (JCAD; also known as KIAA1462) locus to be associated with increased risk of CAD and MI, including rs3739998, rs2505083, and rs2487928.8–11 Recently, rs2487928 has been shown to reduce JCAD expression, which via the Hippo pathway has consequences on a number of downstream phenotypes including angiogenesis.12 In this issue of the European Heart Journal, Xu et al.13 mechanistically examine this interesting question by characterizing Jcad knockout mouse models, performing vascular function studies, and assessing how JCAD modulation affects atherosclerosis development (Figure 1). Scheme illustrating the CAD risk variants at the JCAD locus and the role of JCAD in experimental atherosclerosis. (A) Using a systems genetics approach, Xu et al. demonstrate that the CAD risk variants at the JCAD locus lead to increased JCAD expression. (B) JCAD promotes the activation of the YAP/TAZ pathway and subsequent expression of pro-inflammatory genes. Consequently, endothelial cells express higher levels of VCAM-1 and attract blood monocytes. (C) Jcad-deficient mice develop fewer atherosclerotic lesions that are characterized by a lower accumulation of macrophages and have an improved endothelial-dependent vascular function. CAD, coronary artery disease; EC, endothelial cell; GTEx, Genotype-Tissue Expression database; GWAS, genome-wide association study; HFD, high-fat diet; Mono, monocyte; Recomb. rate, recombination rate. Scheme illustrating the CAD risk variants at the JCAD locus and the role of JCAD in experimental atherosclerosis. (A) Using a systems genetics approach, Xu et al. demonstrate that the CAD risk variants at the JCAD locus lead to increased JCAD expression. (B) JCAD promotes the activation of the YAP/TAZ pathway and subsequent expression of pro-inflammatory genes. Consequently, endothelial cells express higher levels of VCAM-1 and attract blood monocytes. (C) Jcad-deficient mice develop fewer atherosclerotic lesions that are characterized by a lower accumulation of macrophages and have an improved endothelial-dependent vascular function. CAD, coronary artery disease; EC, endothelial cell; GTEx, Genotype-Tissue Expression database; GWAS, genome-wide association study; HFD, high-fat diet; Mono, monocyte; Recomb. rate, recombination rate. The authors initially determined the magnitude and directionality of the association between JCAD risk variants and CAD by mining genotype data from GWAS and expression data from the Genotype-Tissue Expression (GTEx) database. They observed that the lead risk variants associate with increased JCAD expression levels (Figure 1A), that JCAD is highly expressed in endothelial-enriched organs, such as arteries, lungs, and brain, and that the disease-associated JCAD variants map to eQTLs (expression quantitative trait loci) most strongly in arterial tissues—particularly the aorta. Given this association between CAD risk variants and increased JCAD expression, the authors hypothesized that the deletion of Jcad would exert atheroprotective effects in mice. To test their hypothesis, the authors first characterized whole-body Jcad knockout mice. When challenging the mice with a high-fat diet, Jcad knockouts displayed an improved endothelial-dependent vascular relaxation compared with wild-type controls. Surprisingly, although JCAD is a structural membrane protein, vascular permeability was not affected in Jcad knockout mice. To further validate the contribution of JCAD to atherosclerosis, the authors crossbred whole-body and endothelial cell-specific Jcad knockouts with atherosclerosis-susceptible Apoe–/– mice. Both mouse models with Jcad deficiency developed fewer atherosclerotic lesions compared with the control mice upon feeding a high-fat diet. While there were no notable differences in blood lipid levels, smooth muscle cells, collagen content, or inflammation, the authors demonstrate that macrophage staining is reduced in plaques. Consistently, VCAM-1 (vascular cell adhesion molecule 1) expression and monocyte adhesion to mouse endothelial lung cells were reduced in Jcad knockout mice (Figure 1B). Complementary RNA-sequencing studies in coronary artery endothelial cells showed that the expression of various pro-atherogenic genes was reduced, e.g. CTGF and CYR61,14,15 while the expression of atheroprotective genes was increased upon JCAD small interfering RNA (siRNA)-mediated silencing. CTGF and CYR61 are transcriptional targets of the Hippo/YAP/TAZ pathway, further reinforcing this as the mechanistic pathway connecting JCAD to atherosclerosis. The authors performed further gain- and loss-of-function experiments in endothelial cells [i.e human umbilical vein endothelial cells (HUVECs)] to demonstrate that JCAD interacts with several actin-binding proteins and activates the Hippo/YAP/TAZ pathway (Figure 1C), thus leading to the nuclear translocation and transcriptional activation of the complex, and consequently CTGF and CYR61 expression. How is JCAD itself regulated? The authors tested different atherogenic, angiogenic, and biochemical stimuli, and showed that the expression of JCAD is regulated by the blood flow, characterized by increased expression in areas with disturbed flow. Finally, the authors reveal that JCAD expression is increased in the aortic endothelium of mice upon feeding a high-fat diet as well as in advanced human atherosclerotic plaques. The current study of Xu et al. demonstrates that the deletion of Jcad is atheroprotective in mice and suggests that JCAD expression is increased in advanced human plaques. Together with the initial GWAS findings which indicate a causal relationship between JCAD and the incidence of CAD in humans, this study highlights a potential new avenue for understanding and treating arterial diseases. Nevertheless, some questions remain open for future investigations, such as: is the deletion of endothelial cell Jcad sufficient to improve vascular function in mice? This question could be easily addressed with the endothelial cell-specific knockout mouse model. How does blood flow regulate JCAD expression? As described by Jones et al., the RhoA signalling pathway might play a central role in this shear stress response.12 Do the genetic variants that were identified in human GWAS lead to the same phenotype as the Jcad knockout mice? This last question could be addressed by using the CRISPR/Cas9 (clustered regularly interspaced palindromic repeats/CRISPR-associated protein 9) system to introduce the corresponding SNPs in an atherosclerotic mouse model and then assess atherosclerosis development. In a compound screening approach, the authors identified the BRD4 inhibitor JQ1 as a pharmacological inhibitor of JCAD expression. Notably, JQ1 protects against inflammation and development of atherosclerosis.16 It is therefore tempting to speculate that JQ1 may also confer atheroprotection by repressing the expression of JCAD, which would be of high pharmacological interest. GWAS have been established as a powerful tool for the de novo identification of genetic mechanisms affecting complex diseases, yet this approach has been beset by challenges related to the mechanistic understanding of resulting hits. The authors show here a strong example for validating GWAS targets by using a pipeline going from hypothesis discovery in human populations, to mechanistic examination in cell lines, then to genetically modified mice. As JCAD is shown to have a strong impact on atherosclerosis and probably other arterial-related diseases, the authors have established a clear path forward both for additional mechanistic understanding and for clinical examinations in humans. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. We acknowledge support to S.S. by the Swiss National Science Foundation (PZOOP3_161521), the Novartis Foundation for medical-biological Research (#16B103), the Olga-Mayenfisch Foundation, and the OPO Foundation. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2019) conducted an editorial in Coronary artery disease. Jcad deletion vs. Wild-type controls was evaluated on Atherosclerosis development.
Synapse has enriched 10 related papers. Consider them for comparative context: